Latest Manufacturing News

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Structural Monitoring Systems plc has raised $8.7 million and implemented a major cost restructuring, positioning itself for profitable growth with strong sales momentum in its avionics and sensor technology segments.

Althea Group Holdings reported a 20% increase in customer receipts to $9.01 million for Q2 FY25, while addressing governance lapses and reviewing its FY25 guidance. The company is advancing operational improvements and cost savings as it prepares for a pivotal Federal Court hearing.

Aeris Environmental Ltd reported a 5% revenue increase to $766,000 in the December 2024 quarter, driven by strong margins and momentum in its AerisTech joint venture. The company’s expanding customer base and strategic partnerships signal promising growth in smart building solutions and consumables.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

4DS Memory Limited reports successful testing of its 60nm memory cells and progresses toward 20nm technology, alongside a $6 million capital raise and a new design partnership with Infineon.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.

Australian Vanadium Limited reports significant progress in its integrated vanadium supply chain, including government approvals, Project Lumina development, and successful vanadium flow battery deployment.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.